For a tracheostomy patient with recurrent Klebsiella sputum culture who completed cefepime 2 weeks ago and now has a cefepime‑susceptible isolate, should cefepime be restarted and is scopolamine appropriate for controlling tracheostomy secretions?

Management of Recurrent Klebsiella Tracheostomy Infection and Secretion Control

Restart cefepime for the recurrent cefepime-susceptible Klebsiella infection, but scopolamine is NOT an appropriate choice for managing tracheostomy secretions.

Antibiotic Management

Cefepime Re-treatment Decision

You should restart cefepime given the organism remains susceptible, though this situation requires careful consideration:

• The FDA label supports cefepime use for susceptible organisms 1, and the organism's documented susceptibility provides microbiological justification for retreatment
• However, critical caveats exist: Recent research demonstrates that cefepime can fail against certain Klebsiella isolates despite in vitro susceptibility, particularly with carbapenemase-producing strains 2, 3
• The 2-week interval since completing therapy suggests this may represent either relapse (inadequate source control, biofilm) or reinfection rather than treatment failure

Key Clinical Considerations

Before restarting cefepime, you must:

1. Determine if this is true infection versus colonization - Tracheostomy patients commonly have bacterial colonization that doesn't require treatment 4. Only treat if there are signs of active infection (fever, increased oxygen requirements, systemic symptoms, radiographic pneumonia)

2. Assess for carbapenemase production - If the isolate is carbapenem-resistant or produces KPC, cefepime will likely fail even with susceptible MICs 3, 5. Request carbapenemase testing if not already done

3. Evaluate source control - Recurrent infection 2 weeks post-treatment suggests inadequate source control, retained secretions, or biofilm formation on the tracheostomy tube 4

If proceeding with cefepime:

• Use higher dosing (2g IV every 8 hours) for serious respiratory infections 1
• Consider combination therapy rather than monotherapy for improved outcomes 2
• Change the tracheostomy tube if feasible to remove biofilm 4

Alternative Considerations

The 2022 ESCMID guidelines suggest carbapenems remain preferred for serious infections caused by extended-spectrum β-lactamase or AmpC-producing organisms when cefepime MICs are elevated within the susceptible range 6. If this is ESBL-producing Klebsiella, research shows cefepime has significantly worse clinical and microbiological outcomes compared to carbapenems 7.

Secretion Management

Why Scopolamine is Inappropriate

Scopolamine is NOT recommended for tracheostomy secretion management - it is an anticholinergic that dries secretions, which is counterproductive and potentially dangerous in tracheostomy patients.

Evidence-Based Secretion Management

The 2020 NHS NatPatSIP guidelines provide clear direction for managing tracheostomy secretions 8:

Appropriate interventions include:

1. Humidification (first-line) 8:

   • Active water-based humidification to keep secretions loose (every 8 hours)
   • Heat and moisture exchange (HME) filters
   • Monitor daily and increase humidification if secretions thicken

2. Mucolytic agents 8:

   • Saline or hypertonic saline nebulizers
   • These are specifically recommended as useful alternatives or adjuncts

3. Respiratory physiotherapy 8:

   • Every 8 hours for chest clearance
   • Critical component of the multidisciplinary approach

4. Airway clearance techniques 8:

   • Regular suctioning (every 4-8 hours minimum)
   • Closed inline suction systems
   • Inner cannula cleaning every 8-24 hours

Clinical Pitfall

Drying agents like scopolamine will thicken secretions, increasing the risk of mucus plugging and tube occlusion - a potentially fatal complication in tracheostomy patients 9. The Duchenne muscular dystrophy consensus statement specifically warns about mucus plug risk requiring pulse oximetry monitoring 9.

Practical Algorithm

For inability to cap the trach due to secretions:

1. Optimize humidification first (increase to active water-based system)
2. Add hypertonic saline nebulizers
3. Increase respiratory physiotherapy frequency
4. Ensure adequate hydration systemically
5. Consider changing to a cuffed tube if not already in place to facilitate weaning 8
6. Evaluate for underlying infection requiring treatment (which increases secretions)

Never use anticholinergic/drying agents in tracheostomy patients with excessive secretions.